Edition:
United Kingdom

Saumya Joseph

Biogen scraps development of therapy for rare brain disease

2:18pm GMT

Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a therapy for the disorder.

Correvio suffers fresh blow as heart drug fails to win FDA panel backing

10 Dec 2019

Independent experts to the U.S. Food and Drug Administration on Tuesday voted against Correvio Pharma Corp's drug to correct irregular rhythm in the upper chambers of the heart in adult patients, the latest setback to the company's efforts to market a potential blockbuster in the country.

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

09 Dec 2019

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.

Diplomat Pharmacy agrees to $300 million buyout by UnitedHealth

09 Dec 2019

Diplomat Pharmacy Inc on Monday agreed to UnitedHealth Group Inc's over $300 million buyout offer, weeks after it warned of its inability to pay off some of its debt amid intense competition in the pharmacy benefits management business.

Brief visit to severely polluted city can up biomarkers of heart disease

06 Dec 2019

(Reuters Health) - Air pollution has often been linked with increased heart disease risk, but a "natural experiment" involving travelers to a city much more polluted than their own offers clues to how it may harm blood vessels over time, researchers say.

Correvio slumps after FDA staffers say benefits of heart drug do not outweigh risks

06 Dec 2019

U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp's heart drug said on Friday they did not believe the benefits of the therapy outweighed its risks, sending the company's shares down nearly 38%.

Sage shares sink as depression therapy fails much-awaited trial

05 Dec 2019

Sage Therapeutics Inc said on Thursday its experimental fast-acting drug aimed at treating severe depression failed a closely-watched study, sending shares down 60% and erasing about $4.6 billion of the drugmaker's market value.

Large waist in normal-weight elderly tied to higher dementia risk

28 Nov 2019

(Reuters Health) - Older adults with normal weight but a wider waist may be at a higher risk of developing dementia, a Korean study suggests.

CymaBay Therapeutics scraps two studies of liver drug; shares plunge

25 Nov 2019

CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage trials of its liver disease drug, after biopsies found a type of liver damage in some patients, sending its shares down over 75%.

World News